99 related articles for article (PubMed ID: 30595567)
1. Downregulation of Profibrotic Gene Expression by Angiotensin Receptor Blockers.
Nafar M; Samavat S; Shahraki E
Iran J Kidney Dis; 2018 Nov; 12(6):369-375. PubMed ID: 30595567
[TBL] [Abstract][Full Text] [Related]
2. Effect of angiotensin II receptor blocker on plasma levels of TGF-beta 1 and interstitial fibrosis in hypertensive kidney transplant patients.
el-Agroudy AE; Hassan NA; Foda MA; Ismail AM; el-Sawy EA; Mousa O; Ghoneim MA
Am J Nephrol; 2003; 23(5):300-6. PubMed ID: 12904684
[TBL] [Abstract][Full Text] [Related]
3. Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy.
Campistol JM; Iñigo P; Jimenez W; Lario S; Clesca PH; Oppenheimer F; Rivera F
Kidney Int; 1999 Aug; 56(2):714-9. PubMed ID: 10432413
[TBL] [Abstract][Full Text] [Related]
4. Renin-Angiotensin System Blockage and Avoiding High Doses of Calcineurin Inhibitors Prevent Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients.
Sayin B; Canver B; Gurlek Demirci B; Colak T; Ozdemir BH; Haberal M
Exp Clin Transplant; 2017 Feb; 15(Suppl 1):32-36. PubMed ID: 28260428
[TBL] [Abstract][Full Text] [Related]
5. Molecular and clinical response to angiotensin II receptor antagonist in kidney transplant patients with chronic allograft nephropathy.
Mas VR; Alvarellos T; Maluf DG; Ferreira-Gonzalez A; Oliveros L; Maldonado RA; de Boccardo G
Transpl Int; 2004 Oct; 17(9):540-4. PubMed ID: 15349718
[TBL] [Abstract][Full Text] [Related]
6. Effect of losartan on slowing progression of chronic allograft nephropathy.
Wang PX; Fan MQ; Huang CB; Feng JY; Xiao Y; Fang ZQ; Zhang YP
Chin Med Sci J; 2005 Dec; 20(4):231-6. PubMed ID: 16422249
[TBL] [Abstract][Full Text] [Related]
7. Molecular and structural consequences of early renal allograft injury.
Baboolal K; Jones GA; Janezic A; Griffiths DR; Jurewicz WA
Kidney Int; 2002 Feb; 61(2):686-96. PubMed ID: 11849412
[TBL] [Abstract][Full Text] [Related]
8. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta(1) plasma levels in a crossover trial in renal transplant recipients.
Iñigo P; Campistol JM; Lario S; Piera C; Campos B; Bescós M; Oppenheimer F; Rivera F
J Am Soc Nephrol; 2001 Apr; 12(4):822-827. PubMed ID: 11274244
[TBL] [Abstract][Full Text] [Related]
9. Renal allograft protection with angiotensin II type 1 receptor antagonists.
Tylicki L; Biedunkiewicz B; Chamienia A; Wojnarowski K; Zdrojewski Z; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Transplant; 2007 Jan; 7(1):243-8. PubMed ID: 17227571
[TBL] [Abstract][Full Text] [Related]
10. Role of transforming growth factor-beta1 in the progression of chronic allograft nephropathy.
Campistol JM; Iñigo P; Larios S; Bescos M; Oppenheimer F
Nephrol Dial Transplant; 2001; 16 Suppl 1():114-6. PubMed ID: 11369837
[TBL] [Abstract][Full Text] [Related]
11. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
Renke M; Tylicki L; Rutkowski P; Wojnarowski K; Lysiak-Szydlowska W; Rutkowski B
Scand J Urol Nephrol; 2005; 39(6):511-7. PubMed ID: 16303729
[TBL] [Abstract][Full Text] [Related]
12. Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats.
Lavoie P; Robitaille G; Agharazii M; Ledbetter S; Lebel M; Larivière R
J Hypertens; 2005 Oct; 23(10):1895-903. PubMed ID: 16148614
[TBL] [Abstract][Full Text] [Related]
13. Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats.
Wengrower D; Zanninelli G; Latella G; Necozione S; Metanes I; Israeli E; Lysy J; Pines M; Papo O; Goldin E
Can J Gastroenterol; 2012 Jan; 26(1):33-9. PubMed ID: 22288068
[TBL] [Abstract][Full Text] [Related]
14. Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy.
Park HC; Xu ZG; Choi S; Goo YS; Kang SW; Choi KH; Ha SK; Lee HY; Han DS
Nephrol Dial Transplant; 2003 Jun; 18(6):1115-21. PubMed ID: 12748343
[TBL] [Abstract][Full Text] [Related]
15. AT1 antagonist modulates activin-like kinase 5 and TGF-beta receptor II in the developing kidney.
Yim HE; Kim MK; Bae IS; Kim JH; Choi BM; Yoo KH; Hong YS; Lee JW
Pediatr Nephrol; 2006 Oct; 21(10):1377-88. PubMed ID: 16897002
[TBL] [Abstract][Full Text] [Related]
16. Upregulated Expression of Circulating MicroRNAs in Kidney Transplant Recipients With Interstitial Fibrosis and Tubular Atrophy.
Zununi Vahed S; Poursadegh Zonouzi A; Ghanbarian H; Ghojazadeh M; Samadi N; Ardalan M
Iran J Kidney Dis; 2017 Jul; 11(4):309-318. PubMed ID: 28794294
[TBL] [Abstract][Full Text] [Related]
17. Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial.
Praga M; Andrade CF; Luño J; Arias M; Poveda R; Mora J; Prat MV; Rivera F; Galceran JM; Ara JM; Aguirre R; Bernis C; Marín R; Campistol JM
Nephrol Dial Transplant; 2003 Sep; 18(9):1806-13. PubMed ID: 12937228
[TBL] [Abstract][Full Text] [Related]
18. Losartan modulation on NOS isoforms and COX-2 expression in early renal fibrogenesis in unilateral obstruction.
Manucha W; Oliveros L; Carrizo L; Seltzer A; Vallés P
Kidney Int; 2004 Jun; 65(6):2091-107. PubMed ID: 15149322
[TBL] [Abstract][Full Text] [Related]
19. Losartan attenuates paraquat-induced pulmonary fibrosis in rats.
Guo F; Sun YB; Su L; Li S; Liu ZF; Li J; Hu XT; Li J
Hum Exp Toxicol; 2015 May; 34(5):497-505. PubMed ID: 25233898
[TBL] [Abstract][Full Text] [Related]
20. [Transfected miR-1908 inhibits renal fibrosis via targeting transforming growth factor beta 1].
Xie F; Li X; Wei C; Gou L; Dang Y; Shan Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Dec; 31(12):1682-5, 1689. PubMed ID: 26648305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
